Cocrystal Deferred Long Term Liab from 2010 to 2025
| COCP Stock | USD 1.43 0.07 4.67% |
Deferred Long Term Liabilities | First Reported 2010-12-31 | Previous Quarter 48.5 M | Current Value 87.8 M | Quarterly Volatility 62.2 M |
Check Cocrystal Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cocrystal Pharma's main balance sheet or income statement drivers, such as Interest Expense of 1.7 K, Selling General Administrative of 4.1 M or Selling And Marketing Expenses of 8.9 M, as well as many indicators such as Price To Sales Ratio of 383, Dividend Yield of 0.0 or PTB Ratio of 0.69. Cocrystal financial statements analysis is a perfect complement when working with Cocrystal Pharma Valuation or Volatility modules.
Cocrystal | Deferred Long Term Liab |
Latest Cocrystal Pharma's Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Cocrystal Pharma over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Cocrystal Pharma's Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cocrystal Pharma's overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Cocrystal Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 102,418,806 | |
| Geometric Mean | 86,387,089 | |
| Coefficient Of Variation | 60.68 | |
| Mean Deviation | 57,077,270 | |
| Median | 53,905,000 | |
| Standard Deviation | 62,152,228 | |
| Sample Variance | 3862.9T | |
| Range | 136.5M | |
| R-Value | (0.81) | |
| Mean Square Error | 1392.1T | |
| R-Squared | 0.66 | |
| Significance | 0.0001 | |
| Slope | (10,634,935) | |
| Total Sum of Squares | 57943.5T |
Cocrystal Deferred Long Term Liab History
About Cocrystal Pharma Financial Statements
Cocrystal Pharma shareholders use historical fundamental indicators, such as Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although Cocrystal Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in Cocrystal Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Cocrystal Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 48.5 M | 87.8 M |
Additional Tools for Cocrystal Stock Analysis
When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.